Realities of complex therapy of lipitension in comorbid patients at the outpatient stage

V. V. Gorban; Горбань В. В.; I. A. Gerasimenko; Герасименко И. А.; I. V. Kovrigina; Ковригина И. В.; E. S. Kameneva; Каменева Е. С.; E. V. Gorban; Горбань Е. В.

doi:10.18565/pharmateca.2024.6.72-78

Realities of complex therapy of lipitension in comorbid patients at the outpatient stage

Authors: Gorban V.V.¹, Gerasimenko I.A.¹^,2, Kovrigina I.V.¹^,3, Kameneva E.S.¹^,4, Gorban E.V.¹
Affiliations:
1. Kuban State Medical University
2. “Preobrazhenskaya Clinic” LLC
3. Outpatient Department for the Contractual Population of Krasnodar, Research Institute - Regional Clinical Hospital No. 1
4. Policlinic for Specialized Course Outpatient Treatment, Clinical Hospital No. 2
Issue: Vol 31, No 6 (2024)
Pages: 72-78
Section: Cardiology
URL: https://journals.eco-vector.com/2073-4034/article/view/642776
DOI: https://doi.org/10.18565/pharmateca.2024.6.72-78
ID: 642776

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Background. The global spread of lipitension (syntropy of arterial hypertension – AH and dyslipidemia) with damage to target organs and the development of polymorbid pathology dictates the need for its early diagnosis and treatment at the stage of primary health care.

Objective. Evaluation of the effectiveness of combination therapy with antihypertensive drugs (AHDs) and statins in patients with lipitension and comorbid pathology, taking into account the rational use of multipurpose polypills at the outpatient stage.

Methods. Outpatient cards of 240 patients with insufficiently effective antihypertensive therapy were studied in the Kuban State Medical University. An analysis of data physical examination, anthropometry data, blood lipidogram, electrocardiography, therapy with AHDs and statins was carried out.

Results. The prevalence of separate prescription of antihypertensive drugs and lipid-lowering drugs with insufficient AH control (up to 66%) and low-density lipoproteins – LDL (up to 30%) should be accompanied not only by intensification of separate combination therapy, but also by the use of a strategy for treating outpatients with multi-target fixed triple combinations in polypills.

Conclusion. The control of hypertension in 82.1% and LDL-C in 57.1% of patients with lipitension achieved with the use of Equamer when using maximum doses of the components in the polypill (amlodipine, lisinopril, rosuvastatin) may be even more significant.

Keywords

arterial hypertension, dyslipidemia, lipotension, antihypertensive drugs, statins, polypills

Full Text

About the authors

V. V. Gorban

Kuban State Medical University

Author for correspondence.
Email: gorbanvv@mail.ru
ORCID iD: 0000-0001-8665-6796
SPIN-code: 6305-6187

Dr. Sci. (Med.)

Russian Federation, Krasnodar

References

Бойцов С.А., Драпкина О.М., Шляхто Е.В. и др. Исследование ЭССЕ-РФ (Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в регионах Российской Федерации). Десять лет спустя. Кардиоваскулярная терапия и профилактика. 2021;20(5):3007. [Boytsov S.A., Drapkina O.M., Shlyakhto E.V., et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. Cardiovasc Ther Prevent. 2021;20(5):3007. (In Russ.)]. doi: 10.15829/1728-8800-2021-3007.
Горбань В.В., Меньших В.С., Горбань Е.В. Гендерные и возрастные особенности пищевого поведения городского населения с риском развития хронических неинфекционных заболеваний: наблюдательное когортное исследование. Кубанский научный медицинский вестник. 2022;29(1):32–47. [Gorban V.V., Menshikh V.S., Gorban E.V. Gender and age-speciﬁc eating behaviour in urban populations at risk of chronic noncommunicable diseases: an observational cohort study. Kuban Sci Med Bull. 2022;29(1):32–47. (In Russ.)]. doi: 10.25207/1608-6228-2022-29-1-32-47.
Горохова Т. В., Перепеч Н. Б. Возможности применения комбинированной терапии у пациентов c сочетанием артериальной гипертензии и дислипидемии. Российский кардиологический журнал. 2022;27(7):5132. [Gorokhova T.V., Perepech N.B. Potential of combination therapy in patients with hypertension and dyslipidemia. Russ J Cardiol. 2022;27(7):5132. (In Russ.)]. doi: 10.15829/1560-4071-2022-5132.
Ежов М.В., Кухарчук В.В., Сергиенко И.В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. [Ezhov M.V., Kukharchuk V.V. Sergienko I.V., et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russ J Cardiol. 2023;28(5):5471. (In Russ.)]. doi: 10.15829/1560-4071-2023-5471.
Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. [Kobalava Zh. D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V. Arterial hypertension in adults. Clinical guidelines 2020. Russ J Cardiol. 2020;25(3):3786. (In Russ.)]. doi: 10.15829/1560-4071-2020-3-3786.
Кобалава Ж.Д., Кохан Е.В. Артериальная гипертония и гиперхолестеринемия: время анти-«липотензивной» терапии? Рациональная фармакотерапия в кардиологии. 2020;16(5):842–51. [Kobalava Z.D., Kokhan E.V. Hypertension and Hypercholesterolemia: is it Time for Anti-«Lipitensive» Therapy? Rational Pharmacother Cardiol. 2020;16(5):842–51. (In Russ.)]. doi: 10.20996/1819-6446-2020-09-01
Концевая А.В., Шальнова С.А., Драпкина О.М. Исследование ЭССЕ-РФ: эпидемиология и укрепление общественного здоровья. Кардиоваскулярная терапия и профилактика. 2021;20(5):2987. [Kontsevaya A.V., Shalnova S.A., Drapkina O.M. ESSE- RF study: epidemiology and public health promotion. Cardiovasc Ther Prevent. 2021;20(5):2987. (In Russ.)]. doi: 10.15829/1728-8800-2021-2987.
Недогода С.В., Чумачек Е.В., Ледяева А.А. и др. Оптимизация контроля артериального давления, органопротекции и метаболических нарушений с помощью фиксированной комбинации лизиноприл+амлодипин+розувастатин у пациентов с артериальной гипертензией. Российский кардиологический журнал. 2018;4(156):49–55. [Nedogoda S.V., Chumachek E.V., Ledyaeva A.A., et al. Optimal organoprotection, control of blood pressure and metabolic disorder with the fixed combination of lisinopril, amlodipine and rosuvastatin in systemic hypertension. Russ J Cardiol. 2018; 4(156):49–55. (In Russ.)]. doi: 10.15829/1560-4071-2018-4-49-55.
Синеглазова А.В., Фахрутдинова А.Ш., Ким Т.Ю., Парве С.Д. Липитензия и факторы кардиометаболического риска в молодом возрасте. Российский кардиологический журнал. 2024;29(4):5888. [Sineglazova A.V., Fakhrutdinova A.Sh., Kim T.Yu., Parve S.D. Lipitension and cardiometabolic risk factors in young people. Russ J Cardiol. 2024;29(4):5888. (In Russ.)]. doi: 10.15829/1560- 4071-2024-5888.
Стаценко М.Е., Стрельцова А.М. Метаболические эффекты комбинированной терапии рамиприлом и индапамидом у пациентов с артериальной гипертензией и неалкогольной жировой болезнью печени. Артериальная гипертензия. 2021;27(4):472–81. [Statsenko M.E., Streltsova A.M. Metabolic effects of ramipril and indapamide in hypertensive patients with non-alcoholic fatty liver disease. Arter Hypertens. 2021;27(4):472–81 (In Russ.)]. doi: 10.18705/1607-419X-2021-27-4-472-481.
Dalal J.J., Padmanabhan T.N.C., Jain P., et al. LIPITENSION: Interplay between dyslipidemia and hypertension. Indian J Endocrinol Metab. 2012;16(2):240–45. doi: 10.4103/2230-8210.93742.
Gebrie A., Gnanasekaran N., Menon M., et al. Evaluation of lipid profiles and hematological parameters in hypertensive patients: Laboratory-based cross-sectional study. SAGE. Open Med. 2018;6:1–11. doi: 10.177/20503121875663.
Grinshtein Y.u., Ruf R., Shabalin V. Age and gender disparities in the prevalence of lipitension. Eur Heart J. 2021;42(Suppl. 1):ehab724.2318. doi: 10.1093/eurheartj/ehab724.2318.
Gupta A., Whiteley W.N., Godec T., et al. Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial. Eur Heart J. 2024;45:1159–69. doi: 10.1093/eurheartj/ehad814.
Kausik K.R., Ference B.A., Severin T., et al. Global Heart. Word heart federation cholesterol roadmap. 2022; update 28 p. doi: 10.5334/gh.1154.
Rey-Ranal E.M., Cordero A. Most Recent Trials and Advances in Hypertension. Eur Cardiol Rev. 2022;17:e24. doi: 10.15420/ecr.2022.27.
Rikhi R., Bhatia H.S., Schaich C.L., et al. Association of Lipoprotein(a) and Hypertension in Primary Prevention of Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Hypertension. 2023;80(2):352–60. doi: 10.1161/HYPERTENSIONAHA.122.20189.
Xie H., Zhuang Q., Mu J., et al. The relationship between lipid risk score and new-onset hypertension in a prospective cohort study. Front Endocrinol. 2022;13:916951. doi: 10.3389/fendo.2022.916951.